Across TCGA pan-cancer cohorts, RGL3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RGL3 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher RGL3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RGL3 expression acts as an unfavorable survival marker, although some lineages such as OV show a favorable association.

DLBC, OV, and SKCM are the cancer types where RGL3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	24	view →
OV	DFS	Median	III,IV	1.000	0.148	.013	18	view →
SKCM	OS	Median	III,IV	0.230	0.721	.004	9	view →
PRAD	DFS	Median	All	0.431	0.888	<.001	6	view →
GBM	DFS	Median	All	0.081	0.244	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: RGL3 tumor-vs-normal RNA expression · all RGL3 data types